4 May 2020 

Gilead Sciences has secured emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) for remdesivir to treat Covid-19. The authorisation is set to allow broader access to the drug for treating hospitalised patients with severe Covid-19 across the US. Gilead will work with the government to allocate the currently limited supply of the drug. Read the full story here.

The Canadian Government has agreed to provide up to $175.6m funding to support Vancouver-based AbCellera in the identification of antibody-based therapies against Covid-19. The funds will also be used to develop technology and manufacturing infrastructure for antibody treatments for future pandemics.

Researchers at University Hospital Southampton in the UK are conducting a clinical trial to assess a new Covid-19 drug candidate developed by biotech firm Synairgen, according to the BBC. The drug candidate is made of interferon beta that is directly delivered to the airways. Initial data from the trial is set to be available by the end of next month.

Athersys and University Hospitals Cleveland Medical Center (UH Cleveland) have activated the first clinical site for the MACOVIA clinical trial of MultiStem Cell Therapy to treat acute respiratory distress syndrome (ARDS) caused by Covid-19. The primary objective of the study is the number of ventilator-free days through day 28 versus placebo.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.